Chief Executive Officer, Inimmune Inc.
Alan F. Joslyn, Ph.D. Dr. Joslyn has served as Chief Executive Officer of Inimmune since May 2022. Previously he served as CEO, President & Director of Oragenics Inc. until May 2021. Since 2014, Dr. Joslyn has been a partner in Lazarus Pharmaceuticals, LLC. From March 2010 to April 2014, Dr. Joslyn served as CEO and a Director of Sentinella Pharmaceuticals and from August 2009 to October 2012 as CEO and Director of Edusa Pharmaceuticals, both privately held biotechnology companies. From March 2007 to March 2009, Dr. Joslyn served as President and Chief Executive Officer of Mt. Cook Pharma and as Senior Vice President of Research & Development at Penwest Pharmaceuticals from 2004 to 2007. From 1995 to 2004, Dr. Joslyn held a number of leadership positions within Johnson & Johnson and Glaxo focusing on development of gastroenterology products including Propulsid®, Motilium®, Aciphex®, prucalopride and Zofran. Dr. Joslyn received his B.S. in medicinal chemistry, B.A. in biology and Ph.D. in biochemical pharmacology from the State University of New York at Buffalo.